The 2020 National Comprehensive Cancer Network (NCCN) Prostate Cancer Early Detection V2.2020 guidelines and the updated United States Preventive Services Task Force (USPSTF) [15] both acknowledge the benefits of informed and patient-specific (i.e., age, life expectancy, and patient history) PSA screening as a mechanism to reduce overdiagnosis and overtreatment of indolent prostate cancer. This evidence concerns the gene KLK3 and Familial prostate cancer.